12 Month Price Forecast For MGRM
Distance to MGRM Price Forecasts
MGRM Price Momentum
🤔 Considering Monogram Orthopaedics (MGRM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 4:23 AM UTC
MGRM Analyst Ratings & Price Targets
Based on our analysis of 1 Wall Street analysts, MGRM has a consensus that is bullish. The median price target is $5.00, with forecasts ranging from $4.00 to $6.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With MGRM currently trading at $2.85, the median price forecast suggests a 75.4% upside. The most optimistic forecast comes from at , projecting a 110.5% upside, while Jason Wittes at Roth MKM provides the most conservative target, suggesting a 40.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGRM Analyst Consensus
MGRM Price Target Range
Latest MGRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $4.00 |
Stocks Similar to Monogram Orthopaedics Inc. - Common Stock
The following stocks are similar to Monogram Orthopaedics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Monogram Orthopaedics Inc. - Common Stock (MGRM) Financial Data
Monogram Orthopaedics Inc. - Common Stock has a market capitalization of $97.79M with a P/E ratio of -4.7x. The company generates $364,999 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,076.0% and return on equity of -121.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Monogram Orthopaedics Inc. - Common Stock (MGRM) Company Overview
About Monogram Orthopaedics Inc. - Common Stock
Develops patient-optimized orthopaedic implant solutions.
The company generates revenue by producing and marketing robotic surgical equipment, orthopedic implants, and related software designed for reconstructive joint replacement procedures. Its innovative robotic prototypes enhance surgical precision and efficiency, facilitating higher adoption rates among medical professionals.
Founded in 2015 and headquartered in Austin, Texas, Monogram Technologies Inc. was previously known as Monogram Orthopaedics, Inc. The company's focus on advanced surgical technologies positions it well within the growing orthopaedic market, catering to the increasing demand for precision in surgical procedures.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
28
CEO
Mr. Benjamin Sexson C.F.A.
Country
United States
IPO Year
2023
Website
www.monogramorthopedics.comMonogram Orthopaedics Inc. - Common Stock (MGRM) Latest News & Analysis
Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA
1 month agoMonogram Technologies (NASDAQ: MGRM) updated that it has addressed FDA concerns regarding its 510(k) premarket filing for the mBôs TKA System, anticipating a comprehensive response by Q1 2025.
Positive FDA feedback may accelerate Monogram Technologies' product approval timeline, potentially boosting investor confidence and stock value as the market anticipates future growth in orthopedic solutions.
Monogram Technologies Inc. (NASDAQ:MGRM) reported that related parties, including CFO Noel Knape, purchased about $1 million in MGRM common stock. Details are in the Form 8-K filed today.
Insider purchases signal confidence in Monogram's future, potentially boosting investor sentiment and stock price due to perceived undervaluation or positive growth prospects.
Monogram Technologies Inc. (NASDAQ:MGRM) held its Q3 2024 earnings call on November 19, 2024, featuring CEO Ben Sexson and CFO Noel Knape. Participants included Zacks Investment Research.
Monogram Technologies' Q3 earnings call provides insights into financial performance and strategic direction, crucial for assessing future growth and investment potential.
Monogram Technologies Inc. closed a $13 million public offering to support commercialization efforts. A business update call is scheduled for November 19, 2024, at 4:30 p.m. ET.
Monogram Technologies' successful $13 million offering indicates strong investor confidence and funding for growth, crucial for advancing its commercialization strategy in orthopedic surgery.
Monogram Technologies Inc. (NASDAQ:MGRM) will host a conference call on November 19, 2024, at 4:30 PM ET to discuss its Q3 2024 financial results and key milestones.
The upcoming conference call will provide insights into Monogram's financial performance and strategic developments, crucial for assessing its growth potential and market position.
Monogram Technologies Inc. (NASDAQ:MGRM) was named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook, recognizing its reputation in AI-driven orthopedic surgical innovations.
Monogram's recognition enhances its credibility and visibility in the orthopedic market, potentially attracting investors and driving stock value due to increased trust and market interest.
Frequently Asked Questions About MGRM Stock
What is Monogram Orthopaedics Inc. - Common Stock's (MGRM) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Monogram Orthopaedics Inc. - Common Stock (MGRM) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $4.00.
Is MGRM stock a good investment in 2025?
According to current analyst ratings, MGRM has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MGRM stock?
Wall Street analysts predict MGRM stock could reach $5.00 in the next 12 months. This represents a 75.4% increase from the current price of $2.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Monogram Orthopaedics Inc. - Common Stock's business model?
The company generates revenue by producing and marketing robotic surgical equipment, orthopedic implants, and related software designed for reconstructive joint replacement procedures. Its innovative robotic prototypes enhance surgical precision and efficiency, facilitating higher adoption rates among medical professionals.
What is the highest forecasted price for MGRM Monogram Orthopaedics Inc. - Common Stock?
The highest price target for MGRM is $6.00 from at , which represents a 110.5% increase from the current price of $2.85.
What is the lowest forecasted price for MGRM Monogram Orthopaedics Inc. - Common Stock?
The lowest price target for MGRM is $4.00 from Jason Wittes at Roth MKM, which represents a 40.4% increase from the current price of $2.85.
What is the overall MGRM consensus from analysts for Monogram Orthopaedics Inc. - Common Stock?
The overall analyst consensus for MGRM is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are MGRM stock price projections?
Stock price projections, including those for Monogram Orthopaedics Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
